Jetrea (ocriplasmin)
- Region
- 🇪🇺 EU
- Active substance
- ocriplasmin
- Company
- Inceptua AB
- Status
- Withdrawn
- Therapeutic area
- Retinal Diseases
- CHMP opinion
- Thu 17 Jan 2013
- EU approval
- Wed 13 Mar 2013
- Application
- EMEA/H/C/002381
- ATC
- S01XA22
- Official record
- www.ema.europa.eu
Indication
Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
Regulatory milestones
No milestones recorded in the last year.
Follow Jetrea
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.